Erasca, Inc.
ERAS
Rank in Stocks
#3566
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Share Price
$13.68
Last synced: 2026-10-19
Market Cap
$4.78B
Change (1 day)
2.13%
Change (1 year)
455.89%
Country
US
Trade Erasca, Inc. (ERAS)
Category
Healthcare
Stock split history for Erasca, Inc. (ERAS)
Erasca, Inc. stock (symbol: ERAS) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One ERAS share bought prior to Oct 20, 2026 would equal to 0 ERAS shares today.
The most recent stock split occurred on Oct 20, 2026.
One ERAS share bought prior to Oct 20, 2026 would equal to 0 ERAS shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
